Singapore: WuXi PharmaTech, research and technology platform company serving the pharmaceutical, biotechnology, and medical device industries with operations in China and the United States, has entered into a definitive agreement and plan of merger with New WuXi Life Science and its wholly owned subsidiary, WuXi Merger.

New WuXi Life Science will acquire WuXi PharmaTech for cash consideration equal to $5.75 per ordinary share of the company and $46 per American Depositary Share of the company, each representing eight shares or approximately $3.3 billion in aggregate cash consideration.